Armata Q4 net income $2.6M; Phase 2 AP-PA02 positive; $10M credit deal

Armata Pharmaceuticals, Inc.

Q4 net income $2.6M ($0.07 basic, -$0.23 diluted) vs net loss $19.8M YoY; includes $14.2M non-cash gain.
Phase 2 Tailwind study of inhaled AP-PA02 in NCFB showed statistically significant reduction of P.a. CFUs; well-tolerated.
Phase 1b/2a diSArm study of IV AP-SA02 for S. aureus bacteremia enrollment complete; topline data expected H1 2025.
Entered $10M secured credit agreement with Innoviva subsidiary at 14% interest, maturing March 2026; existing loans also extended.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.